Highlights BrainsWay Ltd. OTC Markets

Stocks

BRSY.F

IL0011007189

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 09:54:59 2026-05-06 am EDT			5-day change	1st Jan Change
16.84 ^USD	+24.28%		-.--%	+92.90%

Jun. 09	BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	CI
May. 18	Hopemark Health, Ltd announced that it expects to receive funding from BrainsWay Ltd.	CI

Highlights

Jun. 09	BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	CI
May. 18	BrainsWay Takes Minority Stake in Hopemark Health	MT
May. 13	BrainsWay Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 13	Brainsway Ltd. Reiterates Earnings Guidance for the Year 2026	CI
Mar. 26	Brainsway Provides $6 Million Milestone-Based Convertible Loan to Neurolief	MT
Mar. 11	BrainsWay Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Mar. 11	BrainsWay Ltd. Provides Earnings Guidance for Full Year 2026	CI
Mar. 11	Brainsway Q4 Net Income, Revenue Increases; 2026 Revenue Guidance Issued	MT
Mar. 11	Earnings Flash (BWAY) Brainsway Posts Q4 Revenue $14.5M, vs. FactSet Est of $14M	MT
Mar. 11	Earnings Flash (BWAY) Brainsway Posts Q4 EPS $0.07, vs. FactSet Est of $0.03	MT
Mar. 04	BrainsWay Ltd Unveils Swift Deep TMS Accelerated Treatment For Depression	CI
Jan. 12	BrainsWay Says FDA Grants Premarket Approval to Neurolief's At-Home Depression Treatment	MT
Jan. 12	BrainsWay announces FDA approval of Neurolief's Proliv(TM)Rx neuromodulation system for Major Depressive Disorder (MDD)	RE
Jan. 12	Brainsway Announces Fda Approval of Neurolief?S Proliv?Rx Neuromodulation System for Major Depressive Disorder	CI
Nov. 17	BrainsWay Ltd. Launches First Clinical Trial of Deep TMS 360?? System for Alcohol Use Disorder	CI
Nov. 13	BrainsWay receives FDA clearance of Deep TMS as adjunct therapy for major depressive disorder in adolescents aged 15 to 21	RE
Nov. 13	BrainsWay Ltd. Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21	CI
Nov. 11	BrainsWay Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 11	Brainsway Ltd. Raises Earnings Guidance for the Full-Year 2025	CI
Nov. 11	Brainsway reports third quarter 2025 financial results and operational highlights	RE
Nov. 11	BrainsWay Q3 revenue up 29%, raises full-year forecast	RE
Nov. 01	Serenity Mental Health Centers Expands Access in Colorado Springs with FDA-cleared Accelerated Deep TMS Protocol	CI
25-09-16	BrainsWay Ltd. Announces FDA Clearance of the Cleared Treatment Protocol for the Company's Deep Transcranial Magnetic Stimulation System	CI
25-09-16	BrainsWay gets FDA clearance for accelerated Deep TMS protocol to treat major depressive disorder (MDD)	RE
25-09-16	Brainsway Says US FDA Approves Accelerated Protocol for Major Depression Treatment System	MT